TransMedics Group (NASDAQ:TMDX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of TransMedics Group (NASDAQ:TMDX) from a hold rating to a buy rating in a research report released on Saturday.

TMDX has been the subject of several other reports. Morgan Stanley raised their target price on TransMedics Group from $115.00 to $123.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. Evercore ISI started coverage on shares of TransMedics Group in a report on Tuesday, September 16th. They set an “outperform” rating and a $155.00 price objective for the company. Stifel Nicolaus initiated coverage on shares of TransMedics Group in a research note on Thursday, September 4th. They issued a “hold” rating and a $115.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of TransMedics Group in a research report on Monday, October 13th. They set a “buy” rating and a $145.00 target price for the company. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Monday, August 25th. Seven research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, TransMedics Group has an average rating of “Moderate Buy” and a consensus target price of $127.18.

TransMedics Group Price Performance

TransMedics Group stock opened at $119.90 on Friday. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $145.50. The company’s 50 day moving average price is $116.37 and its two-hundred day moving average price is $114.31. The stock has a market cap of $4.09 billion, a P/E ratio of 62.12 and a beta of 2.08. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.44. The company had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.TransMedics Group’s revenue was up 37.7% on a year-over-year basis. During the same period last year, the business posted $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts predict that TransMedics Group will post 1 earnings per share for the current year.

Institutional Trading of TransMedics Group

A number of institutional investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC bought a new position in TransMedics Group in the 3rd quarter worth approximately $479,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of TransMedics Group during the third quarter worth $741,000. Perigon Wealth Management LLC boosted its holdings in shares of TransMedics Group by 7.3% in the third quarter. Perigon Wealth Management LLC now owns 20,609 shares of the company’s stock worth $2,312,000 after acquiring an additional 1,403 shares during the period. Sapient Capital LLC grew its position in shares of TransMedics Group by 6.1% in the third quarter. Sapient Capital LLC now owns 3,458 shares of the company’s stock valued at $390,000 after purchasing an additional 200 shares in the last quarter. Finally, Precision Wealth Strategies LLC purchased a new position in shares of TransMedics Group in the third quarter valued at $535,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.